

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Apoptotic chromatin condensation inducer 1 (ACIN1; ACN); apoptosis inhibitor 5 (API5)	<p><i>In vitro</i> studies suggest that antagonizing API5 could help increase the efficacy of chemotherapy. In cancer cell lines, API5 knockdown increased cellular apoptosis in response to etoposide and camptothecin. In contrast, API5 overexpression decreased drug-mediated apoptosis. Immunoprecipitation studies showed that ACIN1 and API5 interacted via the leucine zipper region of API5. <i>In vitro</i>, an API5 leucine zipper mimetic prevented the API5-ACIN1 complex from forming and increased chemotherapy-induced apoptosis. Next steps include developing a nonpeptidic molecule to target the leucine zipper region of API5.</p> <p>SciBX 2(17); doi:10.1038/scibx.2009.694 Published online April 30, 2009</p>	Patent application filed in the EU for cancer treatment; available for licensing in the EU	<p>Rigou, P. <i>et al. EMBO J.</i>; published online April 23, 2009; doi:10.1038/emboj.2009.106</p> <p>Contact: Jean-Luc Poyet, Institut National de la Santé et de la Recherche Médicale (INSERM), Paris, France e-mail: jean-luc.poyet@inserm.fr</p>